AstraZeneca (LON:AZN) Earns “Buy” Rating from Shore Capital

Shore Capital restated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Thursday, Marketbeat reports.

AZN has been the subject of several other reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 ($143.19) target price on shares of AstraZeneca in a research note on Tuesday, September 3rd. Berenberg Bank reissued a “buy” rating and issued a £150 ($195.26) price objective on shares of AstraZeneca in a report on Monday, September 2nd. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of £104.12 ($135.54).

AstraZeneca Stock Up 1.8 %

Shares of AZN opened at GBX 9,903 ($128.91) on Thursday. The company has a market capitalization of £153.50 billion, a price-to-earnings ratio of 3,143.81, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 52 week low of GBX 9,461 ($123.16) and a 52 week high of £133.88 ($174.28). The stock’s 50-day moving average price is £118.91 and its 200-day moving average price is £121.58. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97.

Insider Activity at AstraZeneca

In other news, insider Michel Demare acquired 2,000 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were bought at an average price of GBX 118 ($1.54) per share, for a total transaction of £2,360 ($3,072.12). 0.04% of the stock is owned by corporate insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.